CASONATO, SANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.159
AS - Asia 2.669
EU - Europa 1.717
SA - Sud America 349
AF - Africa 102
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 7
Totale 16.011
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.100
SG - Singapore 920
CN - Cina 715
HK - Hong Kong 542
VN - Vietnam 378
BR - Brasile 321
FI - Finlandia 295
DE - Germania 246
SE - Svezia 239
IT - Italia 180
FR - Francia 167
GB - Regno Unito 131
PL - Polonia 113
RU - Federazione Russa 92
UA - Ucraina 79
CI - Costa d'Avorio 58
NL - Olanda 55
AT - Austria 31
IN - India 26
IE - Irlanda 25
CA - Canada 23
BE - Belgio 15
TR - Turchia 14
ES - Italia 10
MA - Marocco 10
MX - Messico 10
BD - Bangladesh 9
IQ - Iraq 9
AR - Argentina 8
JP - Giappone 8
ZA - Sudafrica 8
EC - Ecuador 7
EU - Europa 7
ET - Etiopia 6
UZ - Uzbekistan 6
KE - Kenya 5
SA - Arabia Saudita 5
AU - Australia 4
CO - Colombia 4
DK - Danimarca 4
IL - Israele 4
PA - Panama 4
PH - Filippine 4
RO - Romania 4
AM - Armenia 3
BG - Bulgaria 3
CH - Svizzera 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
HU - Ungheria 3
JM - Giamaica 3
JO - Giordania 3
LA - Repubblica Popolare Democratica del Laos 3
NZ - Nuova Zelanda 3
PK - Pakistan 3
RS - Serbia 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AZ - Azerbaigian 2
BB - Barbados 2
BF - Burkina Faso 2
BO - Bolivia 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
HN - Honduras 2
IR - Iran 2
KR - Corea 2
LT - Lituania 2
LU - Lussemburgo 2
NI - Nicaragua 2
NO - Norvegia 2
PE - Perù 2
PR - Porto Rico 2
UY - Uruguay 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
CU - Cuba 1
DJ - Gibuti 1
EE - Estonia 1
GE - Georgia 1
GR - Grecia 1
HR - Croazia 1
KH - Cambogia 1
KY - Cayman, isole 1
KZ - Kazakistan 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LV - Lettonia 1
MD - Moldavia 1
MG - Madagascar 1
MO - Macao, regione amministrativa speciale della Cina 1
MQ - Martinica 1
MU - Mauritius 1
Totale 16.001
Salva come PNG Salva come JPEG
Città #
Fairfield 1.832
Chandler 1.057
Woodbridge 915
Ashburn 791
Houston 765
Seattle 648
Wilmington 639
Cambridge 618
Ann Arbor 599
Hong Kong 542
Singapore 540
Jacksonville 419
Dong Ket 374
Boardman 247
Princeton 239
Santa Clara 231
San Diego 198
Beijing 192
Medford 136
Roxbury 118
Nanjing 112
Helsinki 109
Bytom 103
Padova 74
Des Moines 61
Abidjan 58
New York 47
Shenyang 38
London 32
Hebei 30
Nanchang 30
Changsha 28
Dublin 25
Los Angeles 24
Norwalk 24
Jiaxing 23
São Paulo 23
Turku 22
Guangzhou 21
Washington 19
Nuremberg 18
Redwood City 17
Vienna 15
Munich 13
Tianjin 12
Indiana 11
Jinan 11
Borås 10
Warsaw 10
Hefei 9
Rio de Janeiro 9
Waanrode 8
Brussels 7
Chicago 7
Kunming 7
Las Vegas 7
Milan 7
Tappahannock 7
Dallas 6
Fuzhou 6
Guardiagrele 6
Kharkiv 6
Kilburn 6
Phoenix 6
San Francisco 6
Tashkent 6
The Dalles 6
Trieste 6
Zhengzhou 6
Addis Ababa 5
Belo Horizonte 5
Brooklyn 5
Curitiba 5
Detroit 5
Florence 5
Frankfurt am Main 5
Manchester 5
Nairobi 5
Sorocaba 5
Southwark 5
Toronto 5
Baghdad 4
Brasília 4
Clifton 4
Dearborn 4
Hangzhou 4
Jacareí 4
Johannesburg 4
Madrid 4
Montreal 4
Nutley 4
Pune 4
Rabat 4
Stockholm 4
Tokyo 4
Amman 3
Amsterdam 3
Atlanta 3
Betim 3
Boston 3
Totale 12.385
Salva come PNG Salva come JPEG
Nome #
1-Desamino-8-D-arginine vasopressin (DDAVP) infusion in type IIB von Willebrand's disease: shortening of bleeding time and induction of a variable pseudothrombocytopenia. 208
Diagnostic Value of Measuring Platelet Von Willebrand Factor in Von Willebrand Disease. 183
Diagnosis and complications of Cushing's disease: gender-related differences. 179
A venous thromboembolism risk assessment model for patients with Cushing’s syndrome 156
Haemostatic patterns and bleeding scores of a genetically characterised Italian family with combined haemophilia A and type 1 von Willebrand disease 155
Venous thrombosis in von Willebrand disease as observed in one centre and as reported in the literature. 146
Type 2B von Willebrand disease with or without large multimers: A distinction of the two sides of the disorder is long overdue 145
A new L1446P mutation is responsible for impaired von Willebrand factor synthesis, structure, and function. 144
Usefulness of the Total Thrombus-Formation Analysis System (T-TAS) in the diagnosis and characterization of von Willebrand disease 141
Type IIB von Willebrand Factor induces phospholipase A2 activation and cytosolic Ca2+ increase in platelets 139
Loss of cysteine 584 impairs the storage and release, but not the synthesis of von Willebrand factor 138
Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. 138
The p.R1819_C1948delinsS mutation makes von Willebrand factor ADAMTS13-resistant and reduces its collagen-binding capacity 137
Severe, recessive type 1 is a discrete form of von Willebrand disease: The lesson learned from the c.1534-3C>A von Willebrand factor mutation 137
Abnormally large von Willebrand factor multimers in Henoch-Schönlein purpura. 136
Coagulation Activation in Children with Sickle Cell Disease Is Associated with Cerebral Small Vessel Vasculopathy 135
Spontaneous hemarthrosis in combined Glanzmann thrombasthenia and type 2N von Willebrand disease. 135
A framework for the optimal design of a minimum set of clinical trials to characterize von Willebrand disease 130
FACTOR-VIII VONWILLEBRAND-FACTOR ABNORMALITIES DURING L-ASPARAGINASE TREATMENT IN PATIENTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA 128
New insight into the Hypercoagulability of Cushing's Syndrome 127
Bernard-Soulier Syndrome: diagnosis by ELISA method using monoclonal antibodies in 2 new unrelated patients 126
von Willebrand factor propeptide makes it easy to identify the shorter von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. 125
Platelet serotonin and platelet aggregation in the differential diagnosis of thrombocytosis 124
Higher and lower active circulating VWF levels: different facets of von Willebrand disease 124
Associated risk factors and arterial occlusions in patients with von Willebrand disease: Analysis of the literature and report of two cases 122
Cryptic noncanonical splice site activation is part of the mechanism that abolishes multimer organization in the c.2269_2270del von Willebrand factor 122
A model-based approach to the automatic diagnosis of von Willebrand disease 121
A new ELISA method for the detection of serum bindable anti-platelet antibodies (SPBIG). 116
von Willebrand factor abnormalities in aortic valve stenosis:pathophysiology and impact on bleeding. 116
The significance of plasma and /or platelet activated products after apheresis procedures 116
Acquired factor VIII:C inhibitor in a patient with Sjögren's syndrome: successful treatment with steroid and immunosuppressive therapy. 115
A model-based support for diagnosing von Willebrand disease 115
Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis. 114
The significance of thrombocytosis in old age 113
Identifying type Vicenza von Willebrand disease 113
Plasma and platelet beta-thromboglobulin levels in patients with May-Hegglin anomaly 113
A novel von Willebrand factor mutation (11372S) associated with type 2B-like von Willebrand disease: An elusive phenotype and a difficult diagnosis 111
Normal and low molecular weight heparins: interaction with human platelets 111
Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series. 111
C2362F mutation gives rise to an ADAMTS13-resistant von Willebrand factor 110
A Mechanistic Model to Quantify von Willebrand Factor Release, Survival and Proteolysis in Patients with von Willebrand Disease 110
Hypercortisolism and pregnancy upregulate von Willebrand factor through different mechanisms: report on a pregnant patient with Cushing's syndrome. 110
The elusive and heterogeneous pattern of type 2M von Willebrand disease: A diagnostic challenge 108
Abnormal collagen binding activity of 2A von Willebrand factor: evidence that the defect depends only on the lack of large multimers. 107
Potentiation of anticoagulant response to warfarin by sulphinpyrazone: a double-blind study in patients with prosthetic heart valves. 107
A frequent factor XII gene mutation in Hageman trait. 105
A study of platelet function and morphology in a new family with May-Hegglin anomaly. 105
Type 2N von Willebrand disease: Characterization and diagnostic difficulties 105
Multiple von Willebrand factor mutations in patients with recessive type 1 von Willebrand disease. 105
Diagnosis and follow-up of thrombotic thrombocytopenic purpura by means of von Willebrand factor collagen binding assay. 105
Combined partial exon skipping and cryptic splice site activation as a new molecular mechanism for recessive type 1 von Willebrand disease. 104
Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia. 104
Inhibitory effect of prostacyclin and nitroprusside on type IIB von Willebrand factor-promoted platelet activation. 103
EDTA dependent pseudothrombocytopenia caused by antibodies against the cytoadhesive receptor of platelet gpIIB-IIIA. 103
Do hemophilia A and von Willebrand disease protect against carotid atherosclerosis? A comparative study between coagulopathics and normal subjects by means of carotid echo-color Doppler scan. 102
Platelet aggregation induced by plasma from type IIB von Willebrand's disease patients is associated with an increase in cytosolic Ca2+ concentration. 102
Biochemical markers of endothelial activation in primary hyperparathyroidism 102
Acquired von Willebrand Syndrome Hiding Inherited von Willebrand Disease Can Explain Severe Bleeding in Patients With Aortic Stenosis. 102
Clinical significance of beta-thromboglobulin in patients with high platelet count 101
A common ancestor more than 10,000 years old for patients with R854Q-related type 2N von Willebrand's disease in Italy. 101
Microsatellite (GT)(n) is part of the von Willebrand factor (VWF) promoter region that influences the glucocorticoid-induced increase in VWF in Cushing's syndrome. 100
Venous thromboembolism in patients with Cushing's syndrome: need of a careful investigation of the prothrombotic risk profile. 100
Coagulopathy in Cushing's syndrome. 97
Type I Padua: a new variant of von Willebrand's disease. 97
Type 3 von Willebrand disease mistaken for moderate haemophilia A: a lesson still to be learned 97
Uneventful coronary artery bypass surgery without prophylatic replacement therapy in a patient with a novel heterozygous FVII gene deletion 97
Combined exon skipping and cryptic splice activation as a new molecular mechanism for recessive type 1 von Willebrand disease. 96
Urokinase-type plasminogen activator release after DDAVP in von Willebrand disease: different behaviour of plasminogen activators according to the synthesis of von Willebrand factor. 96
Type 1 von Willebrand disease due to a vicinal cysteine loss (p.C524Y) disclosed after a thrombotic episode 96
The evaluation of factor VIII antigen by means of a simple slide test. 95
Effect of human recombinant erythropoietin on bleeding time, platelet number and function in children with end-stage renal disease maintained by haemodialysis 95
Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing syndrome 95
Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity? 94
Which assay is the most suitable to investigate von Willebrand factor functional activity? 94
A new congenital platelet abnormality characterized by spontaneous platelet aggregation, enhanced von Willebrand factor platelet interaction, and the presence of all von Willebrand factor multimers in plasma. 94
Type IIb von Willebrand disease: role of qualitative defects in atherosclerosis and endothelial dysfunction. 93
Von Willebrand factor abnormalities in IgA nephropathy. 93
Response to splenectomy in idiopathic thrombocytopenic purpura: prognostic value of the clinical and laboratory evaluation 93
Towards model-based diagnosis of von Willebrand disease 93
75SE-methoinine platelet survival studies: a proposal for a mathematical correction of the curve 92
A model-based protocol for the diagnosis of von Willebrand disease 92
Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis. 92
Discrepancies between von Willebrand factor multimeric composition and other tests in some von Willebrand's disease variants. 91
First report of combined factor VII Padua defect and von Willebrand's disease due to casual association of the two defects. 91
Microsatellite (GT)(n) repeats and SNPs in the von Willebrand factor gene promoter do not influence circulating von Willebrand factor levels under normal conditions. 91
Two novel ITGA2B mutations in a Glanzmann thrombasthaenia family associated with different platelet phenotypic expression 91
The effect of anticoagulant mixtures on BTG and PF4 levels. 90
Demonstration that venous occlusion fails to release von Willebrand factor multimers. 90
An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant. 89
Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. 89
von Willebrand disease investigated by two novel RFLPs. 88
Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization. 88
A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers. 88
Altered von Willebrand factor subunit proteolysis and multimer processing associated with the Cys236Phe mutation in the B2 domain 88
Different organization of von Willebrand factor oligomers in type-2A and -2B von Willebrand disease variants: effects of DDAVP infusion and protease inhibitors. 88
Platelet aggregation and thrombopheresis in thrombocythemia 87
Perioperative thromboprophylaxis in Cushing's disease: What we did and what we are doing? 87
Haplotypes of Von Willebrand factor promoter predict thrombotic risk in Cushing's syndrome 86
Arterial and venous thrombosis in patients with von Willebrand's disease: a critical review of the literature. 86
The effect of increasing heparin doses and of heparinoid on platelet factor 4 (PF4) release in normal subjects. 86
Totale 11.051
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.065
article - articoli 58.795
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.301
Totale 121.161
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020144 0 0 0 0 0 0 0 0 0 0 0 144
2020/20211.894 86 94 54 139 90 148 80 143 251 175 165 469
2021/20222.464 74 256 332 219 69 166 137 310 74 38 302 487
2022/20231.986 387 206 85 238 300 264 4 138 230 8 103 23
2023/2024793 48 114 110 70 70 96 54 28 7 16 92 88
2024/20253.554 9 267 195 188 547 97 143 252 317 107 589 843
Totale 16.114